Table 3.
Adjusted associations between the changes in sphingolipids and the changes in 25(OH)D concentrations *.
| Metabolites | 25(OH)D | |
|---|---|---|
| β (95% CI) | p | |
| C16Cer | 0.13 (−0.31, 0.57) | 0.570 |
| C18Cer | 0.44 (0.02, 0.86) | 0.041 |
| C16dhCer | −0.01 (−0.51, 0.50) | 0.973 |
| C18dhCer | 0.39 (−0.16, 0.93) | 0.161 |
| Sphingosine | 0.08 (−0.68, 0.83) | 0.841 |
| S1P | −0.10 (−0.77, 0.57) | 0.758 |
| C16SM | 0.25 (−0.12, 0.61) | 0.179 |
| C18SM | 0.47 (0.05, 0.90) | 0.030 |
* Mixed-effect linear regression models were adjusted for age, sex, BMI, and baseline 25(OH)D concentrations. Levels of metabolites were standardized. Serum 25(OH)D concentrations were log-transformed. Abbreviations: 25(OH)D, 25-hydroxyvitamin D3; C16Cer, N-palmitoyl-sphingosine (d18:1/16:0); C18Cer, N-stearoyl-sphingosine (d18:1/18:0); C16dhCer, N-palmitoyl-sphinganine (d18:0/16:0); C18dhCer, N-stearoyl-sphinganine (d18:0/18:0); S1P, sphingosine 1-phosphate; C16SM, palmitoyl sphingomyelin (d18:1/16:0); C18SM, stearoyl sphingomyelin (d18:1/18:0).